Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock traded down $0.11 during midday trading on Friday, hitting $2.26. 3,243,605 shares of the company were exchanged, compared to its average volume of 2,345,558. The business has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $3.75. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The firm has a market capitalization of $575.53 million, a PE ratio of -1.38 and a beta of 0.19. Maravai LifeSciences has a fifty-two week low of $1.67 and a fifty-two week high of $10.03.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $46.85 million during the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business's revenue was down 26.9% on a year-over-year basis. On average, sell-side analysts forecast that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on MRVI shares. Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a research report on Friday, March 21st. Craig Hallum dropped their price target on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. UBS Group reduced their price objective on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research note on Friday, March 21st. Finally, Morgan Stanley decreased their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Maravai LifeSciences has an average rating of "Hold" and a consensus target price of $6.64.

Institutional Trading of Maravai LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its position in shares of Maravai LifeSciences by 7.3% in the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company's stock worth $180,000 after acquiring an additional 2,239 shares during the period. Patriot Financial Group Insurance Agency LLC acquired a new position in Maravai LifeSciences in the 4th quarter worth about $136,000. China Universal Asset Management Co. Ltd. raised its holdings in Maravai LifeSciences by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company's stock worth $164,000 after purchasing an additional 2,851 shares during the period. Jennison Associates LLC boosted its position in Maravai LifeSciences by 0.3% during the fourth quarter. Jennison Associates LLC now owns 2,990,414 shares of the company's stock worth $16,298,000 after purchasing an additional 9,769 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its holdings in Maravai LifeSciences by 10.7% in the fourth quarter. E. Ohman J or Asset Management AB now owns 257,751 shares of the company's stock valued at $1,405,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.